FrancophonIA/ELRC3.0 huggingface dataset:
English: • Stop blood clots from forming in your blood in the following situations: o Before and after an operation o When you have an acute illness and face period of limited mobility o When you have unstable angina (a condition when not enough blood gets to your heart) o After a heart attack
Maltese: o Qabel u wara operazzjoni o Meta inti jkollok mard akut u taffaċċja perjodu ta' mobilità limitata o Meta jkollok anġina mhux stabbli (kondizzjoni fejn ma jasalx biżżejjed demm f'qalbek)
English: This includes any possible side effects not listed in this leaflet.
Maltese: Lista totali ta' effetti sekondarji possibbli:
English: Enoxaparin sodium compared to unfractionated heparin significantly decreased the incidence of the primary end point, a composite of death from any cause or myocardial re-infarction in the first 30 days after randomization [9.9 percent in the enoxaparin sodium group, as compared with 12.0 percent in the unfractionated heparin group] with a 17 percent relative risk reduction (p<0.001).
Maltese: 30 jum wara l-għażla b'mod arbitrarju [9.9 fil-mija fil-grupp ta' enoxaparin sodium, meta mqabbel ma' 12.0 fil-mija fil-grupp ta' heparin mhux frazzjonat] bi 17 fil-mija ta' tnaqqis fil-perċentwal tar-riskju relattiv (p<0.
English: NAME OF THE MEDICINAL PRODUCT LOVENOX (and associated names) 10,000 IU (100 mg)/10 mL solution for injection [See Annex I - To be completed nationally] Enoxaparin
Maltese: TAL-PRODOTT MEDIĊINALI LOVENOX (u ismijiet assoċjati) 10,000 UI (100 mg)/10 mL soluzzjoni għall-injezzjoni
English: (subcutaneous).
Maltese: STEMI (NSTEMI).
English: • If you have problems with your kidneys you may be given a smaller amount of LOVENOX (and associated names).
Maltese: • Jekk inti għandek problemi bil-kliewi jista' jkun li tingħata ammont inqas ta' LOVENOX (u ismijiet assoċjati).
English: The full EPAR for Trajenta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: • metformin;
Maltese: • il-metformina;
English: • metformin and a sulphonylurea;
Maltese: • il-metformina u s-sulfonilurea;
English: Other information about Trajenta
Maltese: Informazzjoni oħra dwar Trajenta
English: EPAR summary for the public linagliptin
Maltese: Sommarju tal-EPAR għall-pubbliku linagliptina
English: The active substance in Trajenta, linagliptin, is a dipeptidyl peptidase 4 (DPP-4) inhibitor.
Maltese: Is-sustanza attiva fi Trajenta, il-linagliptina, hija inibitur tad-dipeptidil peptidażi 4 (DPP4).
English: Trajenta is a medicine that contains the active substance linagliptin.
Maltese: Trajenta huwa mediċina li fiha s-sustanza attiva linagliptina.
English: Five main studies in patients with type 2 diabetes were carried out with Trajenta, comparing the medicine with placebo (a dummy treatment) in combination with metformin (701 patients), in combination with metformin plus a sulphonylurea (1,058 patients), in combination with another antidiabetes medicine pioglitazone (389 patients) and in combination insulin with or without metformin and/or pioglitazone (1235 patients).
Maltese: Saru ħames studji ewlenin fuq pazjenti b'dijabete tat-tip 2 bi Trajenta, li qabblu l-mediċina ma' plaċebo (kura finta) f'kombinazzjoni mal-metformina (701 pazjent), f'kombinazzjoni bil-metformina u ssulfonilurea (1,058 pazjent), f'kombinazzjoni ma' mediċina oħra kontra d-dijabete pioglitazone (389 pazjent) u f'kombinazzjoni bejn l-insulina flimkien jew mingħajr il-metformina u/jew il-pijoglitażonu (1235 pazjent).
English: This is a summary of the European public assessment report (EPAR) for Trajenta.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Trajenta.
English: What is the risk associated with Trajenta?
Maltese: X'inhu r-riskju assoċjat ma' Trajenta?
English: The overall risk of side effects with Trajenta was mostly comparable to placebo and the medicine's safety is similar to that of other dipeptidyl peptidase 4 (DPP-4) inhibitor medicines.
Maltese: Ir-riskju ġenerali tal-effetti sekondarji bi Trajenta kien l-aktar komparabbli ma' plaċebo u s-sigurtà talmediċina hija simili għal dik ta' mediċini inibituri tad-dipeptidil peptidażi 4 (DPP-4) oħrajn.
English: Trajenta was also compared with placebo when used on its own in 503 patients.
Maltese: Trajenta tqabbel ukoll ma' plaċebo meta użat waħdu f'503 pazjenti.
English: • when used in combination with metformin, a reduction of 0.56 percentage points was seen with
Maltese: • meta Trajenta ngħata flimkien mal-metaformina, deher tnaqqis ta' 0.56 punti perċentwali meta
English: Trajenta was also more effective than placebo when used on its own, reducing HbA1c levels by 0.46 percentage points compared with a rise of 0.22 percentage points seen with placebo.
Maltese: Trajenta kien ukoll aktar effikaċi mill-plaċebo meta użat waħdu, billi naqqas il-livelli ta' HbA1c b'0.46 punti perċentwali meta mqabbel ma' żieda ta' 0.22 punti perċentwali li dehru bil-plaċebo.
English: What is Trajenta?
Maltese: X'inhu Trajenta?
English: Hypoglycaemia was seen in around 15 out of 100 patients treated with the triple combination of Trajenta with metformin and a sulphonylurea (around twice as many as the placebo group).
Maltese: L-ipogliċemija dehret f'madwar 15 minn kull 100 pazjent ikkurat bil-kombinazzjoni trippla ta' Trajenta mal-metformina u s-sulfonilurea (madwar darbtejn iktar mill-grupp tal-plaċebo).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Trajenta on 24 August 2011.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Trajenta fl-24 ta' Awwissu 2011.
English: How has Trajenta been studied?
Maltese: Kif ġie studjat Trajenta?
English: What benefit has Trajenta shown during the studies?
Maltese: Liema benefiċċju wera Trajenta waqt l-istudji mwettqa?
English: Trajenta on its own was also shown to be effective compared with placebo and was considered appropriate for patients who cannot take metformin either due to intolerance or because they have kidney problems.
Maltese: Trajenta waħdu ntwera wkoll li huwa effettiv meta mqabbel mal-plaċebo u tqies li huwa addattat għal pazjenti li ma jistgħux jieħdu l-metformina jew minħabba intolleranza jew minħabba problemi bil-kliewi.
English: percentage points was seen with Trajenta compared with a rise of 0.10 percentage points with placebo.
Maltese: 72 punti perċentwali meta mqabbel ma' żieda ta' 0.10 punti perċentwali bil-plaċebo;
English: When added to metformin the dose of metformin should remain unchanged, however when combined with a sulphonylurea or insulin, a lower dose of the sulphonylurea or insulin may be considered because of the risk of hypoglycaemia (low blood sugar).
Maltese: Meta miżjud mal-metformina, id-doża ta' metformina għandha tibqa' mhux mibdula, madankollu, meta kkombinata mas-sulfonilurea jew l insulina, tista' tiġi kkunsidrata doża iktar baxxa ta' sulfonilurea jew insulina minħabba r-riskju ta' ipogliċemija (livell baxx ta' zokkor fid-demm).
English: • in combination with pioglitazone, a reduction of 1.25 percentage points was seen with Trajenta compared with a reduction of 0.75 percentage points with placebo;
Maltese: • meta Trajenta ngħata flimkien mal-pijoglitażonu, deher tnaqqis ta' 1.25 punti perċentwali meta
English: In all studies, the main measure of effectiveness was the change in blood levels of a substance called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment.
Maltese: Fl-istudji kollha, il-kejl ewlieni tal-effikaċja kien il-bidla fil-livelli tad-demm ta' sustanza msejħa emoglobina glikosilata (HbA1c) wara 24 ġimgħa ta' kura.
English: Results from studies show that the overall risk of side effects were similar between Trajenta and placebo: (63% versus 60%).
Maltese: (63% kontra 60%).
English: • in combination with insulin with or without metformin and/or pioglitazone, a reduction of 0.55
Maltese: • meta Trajenta ngħata flimkien mal-insulina bil jew mingħajr il-metformina u/jew il-pijoglitażonu,
English: Why has Trajenta been approved?
Maltese: Għaliex ġie approvat Trajenta?
English: For the full list of all side effects reported with Trajenta, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati bi Trajenta , ara l-fuljett ta' tagħrif.
English: By prolonging the action of incretin hormones in the blood, linagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high.
Maltese: Dawn l-ormoni jiġu rilaxxati wara l-ikel u jistimulaw il-produzzjoni tal-insulina mill-frixa.
English: Based on the results of the main studies, the CHMP concluded that significant benefits in controlling blood glucose levels were seen in the combinations of Trajenta with metformin, with metformin plus a sulphonylurea, and with insulin with or without metformin.
Maltese: Fuq il-bażi tar-riżultati tal-istudji ewlenin, is-CHMP ikkonkluda li ntwerew benefiċċji sinifikanti filkontroll tal-livelli tal-glukożju fid-demm fil-kombinazzjonijiet ta' Trajenta mal-metformina, bilmetformina u s-sulfonilurea, u mal-insulina flimkien jew mingħajr il-metformina.
English: Linagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.
Maltese: Il-linagliptina tnaqqas ukoll l-ammont ta' glukożju magħmul mill-fwied, billi żżid il-livelli tal-insulina u tnaqqas illivelli tal-ormon glukagon.
English: The most frequently reported side effect, seen in around 6 out of 100 patients taking Trajenta, was hypoglycaemia.
Maltese: L-effett sekondarju l-aktar irrapportat b'mod komuni, li deher f'madwar 6 minn kull 100 tal-pazjenti li jieħdu Trajenta, kien ipogliċemija.
English: Trajenta was shown to be more effective than placebo at reducing HbA1c levels in all combinations studied:
Maltese: Trajenta ntwera li huwa aktar effikaċi mill-plaċebo fit-tnaqqis tal-livelli ta' HbA1c fil-kombinazzjonijiet kollha studjati:
English: • Educational brochure
Maltese: • Ktejjeb edukattiv
English: • That Tasigna is metabolised by CYP3A4 and that strong inhibitors or inducers of this enzyme may significantly affect exposure to Tasigna.
Maltese: • Li Tasigna jiġi metabolizzat minn CYP3A4 u li impedituri jew indutturi potenti ta' din lenzima jistgħu jeffettwaw b'mod sinifikanti l-esponiment għal Tasigna.
English: • Information on the cardiac risks associated with the use of Tasigna o That Tasigna can cause prolongation of the QT interval and that patients at risk of arrythmia, especially torsade de pointes, should not be prescribed Tasigna.
Maltese: • Informazzjoni dwar ir-riskji kardijaċi assoċjati ma' Tasigna o Li Tasigna tista' jtawwal l-intervall QT u li pazjenti li għandhom riskju ta' arritmija, l-aktar torsade de pointes, m'għandhomx jingħataw riċetti għal Tasigna.
English: o The need to avoid co-prescription with any other medicines that might prolong the QT interval o Caution in prescribing to patients with a history of or risk factors for coronary heart disease o That Tasigna may cause fluid retention, cardiac failure and pulmonary oedema
Maltese: o Li impedituri jistgħu jżidu l-potenzjal għal reazzjonijiet avversi tal-mediċina b'mod partikolari, it-titwil ta' l-intervall QT. o Li javvża l-pazjenti dwar mediċini OTC b'mod partikolari
English: The MAH shall ensure that prior to launch, all doctors who intend to prescribe Tasigna, and all pharmacists who may dispense Tasigna, are provided with a healthcare professional information pack containing the following:
Maltese: L-MAH għandu jiżgura li qabel ma joħroġ fis-suq, it-tobba kollha li jkollhom l-intenzjoni li jordnaw Tasigna, u li l-ispiżjara kollha li jistgħu jagħtu Tasigna, jingħataw pakkett ta' informazzjoni għall-professjonisti fil-qasam tas-saħħa li jkun fih dan li ġej:
English: Key elements to be included in the educational brochure
Maltese: Punti ewlenin li għandhom jiġu inklużi fil-ktejjeb edukattiv
English: • The need to inform patients about the effects of food on Tasigna o Not to eat within two hours before and one hour after taking Tasigna o The need to avoid foods such as grapefruit juice which inhibit CYP3A4 enzymes
Maltese: • Il-bżonn li jinforma l-pazjent dwar l-effetti ta' l-ikel fuq Tasigna o Sabiex ma jieklux fi żmien sagħtejn qabel u siegħa wara li jieħdu Tasigna o Il-bżonn li jevitaw ikel bħall-meraq tal-grejpfrut li jinibixxu l-enzimi CYP3A4
English: • Brief background on Tasigna, its authorised indication and posology
Maltese: • Tagħrif fil-qosor fuq Tasigna, u l-indikazzjoni u l-pożoloġija awtorizzati għaliha.
English: The full EPAR for Tandemact can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is available as tablets (30 mg pioglitazone and 2 or 4 mg glimepiride, or 45 mg pioglitazone and 4 mg glimepiride).
Maltese: Jiġi f'pilloli (30 mg pijoglitażonu u 2 jew 4 mg glimepiride, jew 45 mg pijoglitażonu u 4 mg glimepiride).
English: Other information about Tandemact
Maltese: Informazzjoni oħra dwar Tandemact
English: The European Commission granted a marketing authorisation valid throughout the EU for Tandemact on 8 January 2007.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha għal Tandemact fit8 ta' Jannar 2007.
English: The patients' HbA1c levels fell from a baseline of over 7.5% by between 1.22 and 1.64%.
Maltese: Il-livelli tal-HbA1c tal-pazjenti, li fil-bidu kienu jaqbżu l-linja bażi ta' 7.5%, waqgħu b'bejn 1.22% u 1.64%.
English: Glimepiride is a sulphonylurea: it stimulates the pancreas to produce more insulin.
Maltese: Il-glimepiride hija sulfonilurea: tistimula l-frixa biex tipproduċi aktar insulina.
English: Tandemact pioglitazone and glimepiride
Maltese: Tandemact pijoglitażone u glimepiride
English: The most common side effects with Tandemact (seen in between 1 and 10 patients in 100) are upper respiratory tract infections (such as colds), hypoaesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas) and oedema (swelling).
Maltese: L-effetti sekondarji l-aktar komuni b'Tandemact (li dehru f'bejn pazjent 1 u 10 minn 100) huma infezzjonijiet tal-parti ta' fuq tal-passaġġ respiratorju (irjiħat), ipostesija (tnaqqis fis-sensittività talmess), ksur fl-għadam, żieda fil-piż, sturdament, flatulenza (gass) u oedema (nefħa).
English: Because pioglitazone has been approved in the European Union (EU) since 2000 under the name Actos, and glimepiride is already used in authorised medicines in the EU, the company presented data obtained in earlier studies and from the published literature.
Maltese: Peress li l-pijaglitażonu ilha approvata mill-Unjoni Ewropea (UE) sa mill-2000 bl-isem Actos, u lglimepiride diġà qed tintuża f'mediċini awtorizzati fl-UE, il-kumpanija ressqet data miksuba minn studji preċedenti u mid-dokumentazzjoni ppubblikata.
English: These studies used pioglitazone and sulphonylureas given as separate tablets.
Maltese: Tliet studji użaw il-pijoglitażonu u d-diversi tipi ta' sulfonilurea f'pilloli separati.
English: What is the risk associated with Tandemact?
Maltese: X'inhu r-riskju assoċjat ma' Tandemact?
English: Tandemact is a medicine that contains two active substances, pioglitazone and glimepiride.
Maltese: Tandemact huwa mediċina li fiha żewġ sustanzi attivi, il-pijoglitażonu u il-glimepiride.
English: What is Tandemact?
Maltese: X'inhu Tandemact?
English: This is a summary of the European public assessment report (EPAR) for Tandemact.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Tendemact.
English: At least 64% of the patients treated were classified as ‘responders', since their HbA1c levels either fell by at least 0.6% from the baseline value over the course of the studies, or their HbA1c levels were 6.1% or less at the end of the studies.
Maltese: Mill-inqas 64% tal-pazjenti li ngħataw il-kura ġew ikklassifikati bħala ‘responders', peress li matul l-istudji l-livelli tal-HbA1c tagħhom waqgħu b'mill-inqas 0.6% mill-valur tal-linja bażi, jew fi tmiem l-istudji l-livelli tal-HbA1c tagħhom kienu 6.1% jew inqas.
English: The company that markets Tandemact will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Maltese: Il-kumpanija li tqiegħed Tandemact fis-suq se tipproduċi materjal edukattiv għat-tobba li jippreskrivu lmediċina, li se jkopri r-riskju possibbli ta' insuffiċjenza tal-qalb u kanċer fil-bużżieqa tal-urina bil-kuri li fihom il-pijoglitażonu, il-kriterji għall-għażla tal-pazjenti u l-ħtieġa ta' rieżami regolari tal-kura u li lkura titwaqqaf jekk il-pazjenti ma jibqgħux jibbenefikaw minnha.
English: How has Tandemact been studied?
Maltese: Kif ġie studjat Tandemact?
English: The studies included 1,390 patients who added pioglitazone to their existing treatment with a sulphonylurea.
Maltese: L-istudji involvew 1,309 pazjenti li żiedu l-pijoglitażonu mal-kura li kienu diġa qed jirċievu b'xi sulfonilurea.
English: Patients who are receiving pioglitazone together with another medicine in the same class as glimepiride (i.e. another sulphonylurea) should first be switched from this other sulphonylurea to glimepiride before they can transfer to Tandemact.
Maltese: Il-pazjenti li jkunu qed jingħataw ilpijoglitażonu flimkien ma' mediċina oħra tal-istess klassi bħall-glimepiride (jiġifieri sulfonilurea oħra) lewwel jenħtieġ li jaqilbu minn din is-sulfonilurea l-oħra għall-glimepiride qabel ma jibdew jieħdu Tandemact.
English: It is used in patients for whom metformin (a type of diabetes medicine) is not suitable and who are already being treated with a combination of tablets containing the two active substances pioglitazone and glimepiride.
Maltese: Jintuża f'pazjenti li ma jistgħux jingħataw il-metformina (tip ta' mediċina kontra d-dijabetika) u li diġà jkunu qed jingħataw kura b'kombinazzjoni ta' pilloli li jkun fihom iż-żewġ sustanzi attivi, il-pijoglitażonu u l-glimepiride.
English: Why has Tandemact been approved?
Maltese: Għaliex ġie approvat Tandemact?
English: The studies lasted between four months and two years and measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Maltese: L-istudji, li damu bejn erba' xhur u sentejn, kejlu l-livell ta' sustanza fid-demm magħrufa bħala emoglobina glikosilata (HbA1c), li tagħti indikazzjoni ta' kemm ikun ikkontrollat tajjeb il-glukożju fid-demm.
English: Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Maltese: Ilpijoglitażonu tagħmel iċ-ċelloli (ix-xaħam, il-muskoli u l-fwied) iktar sensittivi għall-insulina, li jfisser li lġisem jagħmel użu aħjar mill-insulina li jipproduċi.
English: How does Tandemact work?
Maltese: Għal xiex jintuża Tandemact?
English: The full EPAR for Xalkori can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Xalkori is available as capsules (200 mg and 250 mg).The recommended dose is 250 mg twice per day.
Maltese: Xalkori jiġi bħala kapsuli (200 mg u 250 mg).
English: This is a summary of the European public assessment report (EPAR) for Xalkori.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Xalkori.
English: Other information about Xalkori
Maltese: Informazzjoni oħra dwar Xalkori
English: The active substance in Xalkori, crizotinib, is an RTK inhibitor.
Maltese: Is-sustanza attiva f'Xalkori, il-krizotinib, hija inibitur ta' RTK.
English: A study in 53 ROS1-positive patients with advanced disease showed that around 70% of patients taking Xalkori (37 out of 53) responded completely or partially to treatment.
Maltese: Studju fuq 53 pazjent pożittivi għar-ROS1 b'marda avvanzata wera li madwar 70% tal-pazjenti li ħadu Xalkori (37 minn 53) irrispondew kompletament jew parzjalment għall-kura.
English: The most common side effects with Xalkori (seen in more than 1 in 4 patients) are vision problems, nausea (feeling sick), diarrhoea, vomiting, oedema (swelling), increases in liver enzymes in the blood, decreased appetite, constipation, dizziness, neuropathy (pain due to nerve damage) and tiredness.
Maltese: L-effetti sekondarji l-aktar komuni b'Xalkori (li dehru f'aktar minn pazjent 1 minn kull 4) huma problemi fil-vista, nawżja (tħossok ma tiflaħx), dijarea, rimettar, edema (nefħa), żieda fl-enżimi talfwied fid-demm, nuqqas fl-aptit, stitikezza, sturdament, newropatija (uġigħ minħabba ħsara finnervituri) u għeja.
English: Xalkori crizotinib
Maltese: Xalkori krizotinib
English: ROS1-positive NSCLC
Maltese: NSCLC pożittiv għar-ROS1
English: This means that the cancer cells contain changes affecting the gene responsible for the protein ROS1.
Maltese: Dan ifisser li ċ-ċelloli tal-kanċer ikun fihom bidliet li jaffettwaw lill-ġene responsabbli mill-proteina ROS1.
English: The most serious side effects are liver damage, pneumonitis (lung inflammation), neutropenia (low blood levels of neutrophils, a type of white blood cell) and prolonged QT interval (a problem with the electrical activity of the heart).
Maltese: L-effetti sekondarji l-aktar serji huma tossiċità fil-fwied, pnewmonite (infjammazzjoni tal-pulmun), newtropenija (livelli baxxi ta' newtrofili fid-demm, tip ta' ċellola taddemm bajda) u intervall QT imtawwal (problema bl-attività elettrika tal-qalb).
English: • It is also used when the NSCLC is ‘ROS1-positive'.
Maltese: • Jintuża wkoll meta l-NSCLC ikun 'pożittiv għar-ROS1'.
English: ALK and ROS1 belong to a family of proteins called receptor tyrosine kinases (RTKs), which are involved in the growth of cells.
Maltese: ALK u ROS1 jagħmlu parti minn familja ta' proteini magħrufin bħala riċettur tal-kinażijiet tat-tirożina (RTKs), li huma involuti fit-tkabbir ta' ċelloli.
English: Why is Xalkori approved?
Maltese: Għaliex ġie approvat Xalkori?
English: Xalkori contains the active substance crizotinib.
Maltese: Xalkori fih is-sustanza attiva krizotinib.
English: If certain side effects develop the doctor may decide to interrupt or reduce the dose to 200 mg twice per day then to 250 mg once per day.
Maltese: Jekk jiżviluppaw ċerti effetti sekondarji, it-tabib jista' jiddeċiedi li jinterrompi jew inaqqas id-doża għal 200 mg darbtejn kuljum imbagħad għal 250 mg darba kuljum.
English: Xalkori is a cancer medicine used on its own to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC), when the disease is advanced:
Maltese: Xalkori huwa mediċina kontra l-kanċer li jintuża waħdu fil-kura ta' adulti b'tip ta' kanċer tal-pulmun magħruf bħala kanċer tal-pulmun mhux taċ-ċelloli żgħar (NSCLC), meta l-marda tkun avvanzata:
English: In another study in 343 patients who had not received previous treatment for their NSCLC before, patients treated with Xalkori lived on average for nearly 11 months without their disease getting worse compared with 7 months in patients who were treated with pemetrexed-containing therapy.
Maltese: Fi studju ieħor fuq 343 pazjent li ma kinux ikkurati qabel għall-NSCLC tagħhom, il-pazjenti li kienu kkurati b'Xalkori għexu medja ta' kważi 11-il xahar mingħajr ma l-marda tagħhom marret għall-agħar meta mqabbla ma' 7 xhur f'pazjenti li kienu kkurati b'terapija li kien fiha pemetrexed.
English: This is considered a favourable response when compared with response rates of around 20 to 30% to previous treatments, in those patients who had been given them.
Maltese: Dan huwa kkunsidrat rispons favorevoli meta mqabbel mar-rati ta' rispons ta' madwar 20 sa 30% għal kuri ta' qabel, f'dawk il-pazjenti li ngħatawlhom.